Statins and cognitive function in the elderly: the Cardiovascular Health Study

Area of Science:

• Gerontology
• Neuroscience
• Pharmacology

Background:

• Cognitive decline is a significant concern in aging populations.
• Statins are widely prescribed cholesterol-lowering medications.
• The impact of statins on cognitive function in the elderly remains an area of active research.

Purpose of the Study:

• To investigate the association between statin use and changes in cognitive function and brain structure (MRI) in older adults.
• To determine if statin's effects on cognition are independent of their lipid-lowering properties.

Main Methods:

• Analysis of data from the Cardiovascular Health Study, a longitudinal study of individuals aged 65 and older.
• Classification of participants into continuous statin users, intermittent users, and non-users.
• Assessment of cognitive decline using the Modified Mini-Mental State Examination (3MS) over 7 years and MRI-based white matter changes and atrophy over 5 years.
• Exclusion of participants with stroke, TIA, or very low baseline cognitive scores.

Main Results:

• Statin users showed a trend towards a slower rate of cognitive decline (0.48-0.49 points/year less on 3MS) compared to untreated groups, even after controlling for cholesterol levels.
• No significant differences were found in white matter grade changes or brain atrophy measures between statin users and non-users on MRI.
• The beneficial effect on cognition was statistically significant in one comparison group (p=0.009).

Conclusions:

• Statin drug use is associated with a modest reduction in cognitive decline among the elderly.
• The observed cognitive benefits of statins may not be solely attributable to their cholesterol-lowering effects.
• Further research is needed to elucidate the mechanisms behind statin's potential neuroprotective effects.